886499-50-9

Usage

Uses

Used in Pharmaceutical Industry:
3-(3,4,5-TRIFLUOROPHENYL)PROPIONIC ACID is used as an antipsychotic medication for the treatment of schizophrenia, bipolar disorder, and other psychotic disorders. It functions by blocking the action of dopamine and serotonin in the brain, which helps to alleviate the symptoms of these mental health conditions.
Used in Anti-inflammatory Applications:
3-(3,4,5-TRIFLUOROPHENYL)PROPIONIC ACID has shown potential as an anti-inflammatory agent, which may have applications in the treatment of pain and inflammation. Its ability to modulate inflammatory pathways could provide relief for various inflammatory conditions.
Used in Research and Development:
3-(3,4,5-TRIFLUOROPHENYL)PROPIONIC ACID is utilized in research and development due to its unique chemical properties and potential therapeutic effects. Its exploration in scientific studies can lead to the discovery of new applications and a deeper understanding of its mechanisms of action.

InChI:InChI=1/C9H7F3O2/c10-6-3-5(1-2-8(13)14)4-7(11)9(6)12/h3-4H,1-2H2,(H,13,14)

Relevant academic research and scientific papers

A step toward direct fullerene synthesis: C60 fullerene precursors with fluorine in key positions

Several fluorine containing polycyclic aromatic hydrocarbons with exact carbon atom topology of the C60 fullerene have been synthesized. Different numbers of fluorine atoms were introduced in the key positions, as needed for an efficient intramolecular condensation to the fullerene molecule. The polycyclic aromatic compounds obtained represent attractive precursors for rational, high-yield fullerene synthesis by flash vacuum pyrolysis.

5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES

The invention relates to 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives of formula (I),wherein X represents CH2 or O; R1 represents a phenyl group, which group is independently mono-, di-, or tri-substituted wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, halogen, cyano, trifluoromethoxy and trifluoromethyl; R2 represents (C1-4)alkyl, (C1-4)alkoxy, (C2-4)alkenyl, halogen, cyano, hydroxymethyl, trifluoromethyl, C(O)NR5R6 or cyclopropyl; R3 represents (C1-4)alkyl, (C1-4)alkoxy-methyl or halogen; R4 represents (C1-4)alkyl; R5 represents hydrogen or (C1-4)alkyl; and R6 represents hydrogen or (C1-4)alkyl. The invention also relates to pharmaceutically acceptable salts of such compounds; and to the use of such compounds as medicaments; especially as orexin receptor antagonists.